Reviewing Calidi Biotherapeutics (NYSE:CLDI) & Candel Therapeutics (NASDAQ:CADL)

Calidi Biotherapeutics (NYSE:CLDI) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Calidi Biotherapeutics and Candel Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calidi Biotherapeutics	N/A	N/A	-344.45%
Candel Therapeutics	N/A	-629.29%	-173.39%

Insider and Institutional Ownership

12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Calidi Biotherapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500.

Valuation and Earnings

This table compares Calidi Biotherapeutics and Candel Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calidi Biotherapeutics	$50,000.00	261.28	-$29.22 million	N/A	N/A
Candel Therapeutics	$120,000.00	1,970.80	-$37.94 million	($1.75)	-2.74

Calidi Biotherapeutics has higher earnings, but lower revenue than Candel Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Calidi Biotherapeutics and Candel Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calidi Biotherapeutics	0	0	2	0	3.00
Candel Therapeutics	0	0	4	0	3.00

Calidi Biotherapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 3,168.69%. Candel Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 337.50%. Given Calidi Biotherapeutics’ higher probable upside, equities analysts plainly believe Calidi Biotherapeutics is more favorable than Candel Therapeutics.

Summary

Candel Therapeutics beats Calidi Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.